Veru Inc (NASDAQ:VERU) Sellers Reduced By 9.49% Their Shorts As Of Jun 27, 2018

June 27, 2018 - By Samuel McNeil

Veru Inc (NASDAQ:VERU) reported a decrease of 9.49% in short interest. In June was issued VERU’s total 360,700 short interest by FINRA. The down change of 9.49% from 398,500 shares was reported. Previous VERU’s position will need 4 days to recover. It has 97,000 average volume. Float short on Veru Inc is 1.27%.

The stock decreased 0.89% or $0.02 during the last trading session, hitting $2.22.Veru Inc. has 148,029 shares volume, 26.95% up from normal. VERU is uptrending and has moved 65.00% since June 27, 2017. VERU outperformed by 52.43% the S&P500.

Veru Inc., a medical therapeutics company, develops, makes, and markets consumer health care products.The company has $118.80 million market cap. The companyÂ’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever.Currently it has negative earnings. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus.

Another two news for Veru Inc. (NASDAQ:VERU) were briefly announced by: Globenewswire.com on June 12, 2018 with title “Veru to Start Phase 2 Trial to Evaluate Cis-Clomiphene Citrate to Treat Hot Flashes Caused by Advanced Prostate …”. The other Nasdaq.com‘s article was titled “Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th” and announced on May 30, 2018.

Veru Inc. (NASDAQ:VERU) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.